-
YAP1 (BSB-146)
YAP1 (BSB-146)
- 中文名称：
- YAP1 (BSB-146)
- 英文名称：
- YAP1 (BSB-146)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59397
- 规格：
- 5 Slides|3 mL (RTU)|0.1 mL (Concentrate)|7 mL (RTU)|0.5 mL (Concentrate)
- 保存建议：
- Store at 2-8 degree C (Control Slides: Store at 20-25 degree C)
This product is stable up to the expiration date on the product label.
Do not use after expiration date listed on the package label. Temperature fluctuations should be avoided. Store appropriately when not in use, and avoid prolonged exposure to room temperature conditions.
- 货期：
- 6-8周
- 来源宿主：
- Mouse
- 反应种属：
- Human, Mouse, Rat
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 其他：
克隆性:Monoclonal
同型:IgG1
克隆号:[BSB-146]
特异性:N/A
纯度:N/A
形式：Paraffin, Frozen
YAP1 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH7.5, containing BSA and sodium azide as a preservative.
浓度：N/A
- 说明书：
Yes-Associated Protein 1 (YAP1) is a regulatory protein that binds the Src family tyrosine kinase YES, promotes transcriptional activation of cyclin E and inhibition of caspase-induced apoptosis. YAP1 is found in the cytoplasm, though transported into the nucleus to perform its roles in proliferation and assist in tissue repair and growth. YAP1 is essential for cancer growth, contributing to stem-cell-like features of proliferation and metastasis and inducing these features in neighboring cells. YAP1 may be upregulated or have higher nuclear localization in more malignant and metastatic tumors, as seen in Lung, Breast, Colorectal, Liver, Gastric, Pancreatic, and Brain Cancers.
YAP1 antibody It is frequently overexpressed in Mammary carcinoma, Glioblastoma and Squamous Cell Carcinoma, Pancreatic, Oral, Cervical, Ovarian and Lung Cancers. YAP1 has been found to be expressed in fetal and adult brain regions known to harbor neural progenitor cells but there was little YAP1 immunoreactivity in the adult cerebral cortex. YAP1 protein was also readily detected in the nuclei of human brain tumors. In Medulloblastoma, expression varied between histologic subtypes and was most prominent in Nodular/Desmoplastic tumors. In Gliomas it was frequently expressed in infiltrating Astrocytomas and Oligodendrogliomas, but rarely in Pilocytic Astrocytomas. YAP1 antibody immunoreactivity has been found in the nuclei of tumor cells in 64.8% of Clear Cell Renal Cell Carcinoma (ccRCC) patients, whereas only 24.1% of tumors revealed cytoplasmic YAP1 expression with ccRCC patients having cytoplasmic YAP1 immunoexpression had significantly shorter OS (median = 26.8 months) than patients without cytoplasmic YAP1 and concluded that increased cytoplasmic YAP1 (HR = 4.53) and decreased LATS1 immunoreactivity levels (HR = 0.90) were associated with worse prognosis, being independent prognostic factors. These results suggest that YAP1 and LATS1 can be considered as new prognostic factors in ccRCC.
